Abstract
Optimal treatment of the impaired mobility that results from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. The overarching objectives of MOBILISE-D are threefold: to deliver a valid solution (consisting of sensor, algorithms, data analytics, outcomes) for realworld digital mobility assessment; to validate digital outcomes in predicting clinical outcome in chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis and hip fracture recovery; and, to obtain key regulatory and health stakeholder approval for digital mobility assessment. The objectives address the call directly by linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice. MOBILISE-D consists of 22 partners from 11 countries with long, successful collaboration history, bringing together all of the requisite expertise to address the technical and clinical challenges. To achieve the objectives, the partners will jointly develop and implement a digital mobility assessment solution that demonstrates that real-world digital mobility outcomes can successfully predict relevant clinical outcomes and provide a better, safer and quicker way to arrive at the development of innovative medicines. MOBILISE-D's results will directly facilitate drug development, and establish the roadmap for the clinical implementation of new, complementary tools to identify, stratify and monitor disability, so enabling widespread, cost-effective access to optimal clinical mobility management through personalised healthcare.
Project details
Unibo Team Leader: Lorenzo Chiari
Unibo involved Department/s:
Dipartimento di Ingegneria dell'Energia Elettrica e dell'Informazione "Guglielmo Marconi"
Dipartimento di Ingegneria Industriale
Coordinator:
Newcastle University(United Kingdom)
Other Participants:
University of Northumbria
(United Kingdom)
The University Of Sheffield Usfd
(United Kingdom)
Grunenthal Gmbh
(Germany)
ALMA MATER STUDIORUM - Università di Bologna
(Italy)
Norges Teknisk Naturvitenskapelige Universitet Ntnu
(Norway)
University Of Zurich
(Switzerland)
Microsoft Research Ltd
(United Kingdom)
Katholieke Universiteit Leuven
(Belgium)
Centre Hospitalier Universitaire Montpellier
(France)
Christian-Albrechts Universität Zu Kiel
(Germany)
Mcroberts Bv
(Netherlands)
Fundacion Privada Instituto De Salud Global Barcelona
(Spain)
eResearchTechnology, Inc.
(United States of America)
Penumologisches Forschungsinstitut An Der Lungenclinic Grosshansdorf Gmbh
(Germany)
Merck KGaA
(Germany)
University College Dublin (Ucd)
(Ireland)
Libera Università Vita Salute S.Raffaele MILANO
(Italy)
Pfizer Limited
(United Kingdom)
Sanofi-Aventis Recherche & Developpement
(France)
Teva Pharmaceutical Industries Limited
(Israel)
Novartis Pharma Ag
(Switzerland)
ICON Clinical Research Limited
(Ireland)
Astrazeneca Ab
(Sweden)
Imperial College London
(United Kingdom)
Bayer Ag
(Germany)
Robert Bosch Gesellschaft Fuer Medizinische Forschung (Rbmf)
(Germany)
Universitatsklinikum Erlangen
(Germany)
The Foundation For Medical Researchinfrastructuraldevelopment And Health Services Next To The Medical Center Tel Aviv
(Israel)
Amgen Limited
(United Kingdom)
Ixscient Limited
(United Kingdom)
Takeda Development Centre Europe Ltd
(United Kingdom)
Epfl Ecole Politechnique Federale De Lausanne
(Switzerland)
Friedrich Alexander Universitaet Erlangen Nuernberg
(Germany)
Università degli Studi di SASSARI
(Italy)
Total Eu Contribution: Euro (EUR) 25.395.897,00
Project Duration in months: 63
Start Date:
01/04/2019
End Date:
30/06/2024
Cordis webpage
Project website
This project contributes to the achievement of the Sustainable Development Goals of the UN 2030 Agenda.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 820820